Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 17, 2017 – Genentech announced the FDA approval of Lucentis (ranibizumab) for the treatment of patients with diabetic retinopathy (DR).
Download PDF
Return to publications
